United Nations Office on Drugs and Crime. World drug report 2024. Vienna: United Nations; 2024.

Book  Google Scholar 

Farrell M, Martin NK, Stockings E, Borquez A, Cepeda JA, Degenhardt L, et al. Responding to global stimulant use: challenges and opportunities. Lancet. 2019;394:1652–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edn. Arlington, VA: American Psychiatric Association; 2013. dsm.psychiatryonline.org. Accessed 1 June 2013.

Potvin S, Pelletier J, Grot S, Hébert C, Barr AM, Lecomte T. Cognitive deficits in individuals with methamphetamine use disorder: a meta-analysis. Addict Behav. 2018;80:154–60.

Article  PubMed  Google Scholar 

Sabrini S, Wang GY, Lin JC, Ian JK, Curley LE. Methamphetamine use and cognitive function: a systematic review of neuroimaging research. Drug Alcohol Depend. 2019;194:75–87.

Article  CAS  PubMed  Google Scholar 

Degenhardt L, Glantz M, Evans-Lacko S, Sadikova E, Sampson N, Thornicroft G, et al. Estimating treatment coverage for people with substance use disorders: an analysis of data from the World Mental Health Surveys. World Psychiatry. 2017;16:299–307.

Article  PubMed  PubMed Central  Google Scholar 

Cumming C, Troeung L, Young JT, Kelty E, Preen DB. Barriers to accessing methamphetamine treatment: a systematic review and meta-analysis. Drug Alcohol Depend. 2016;168:263–73.

Article  PubMed  Google Scholar 

St. Peters MM, Park CHJ, Turner A, Guerin AA, Kim JH. Past and current drug repurposing clinical trials to treat cognition in methamphetamine use: a scoping review of pharmacotherapy candidates. Addict Neurosci. 2023;5: 100064.

Article  Google Scholar 

Siefried KJ, Acheson LS, Lintzeris N, Ezard N. Pharmacological treatment of methamphetamine/amphetamine dependence: a systematic review. CNS Drugs. 2020;34:337–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005;75:406–33.

Article  CAS  PubMed  Google Scholar 

Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394:1560–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bell J. Pharmacological maintenance treatments of opiate addiction. Br J Clin Pharmacol. 2014;77:253–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2014:Cd002207.

Unodc NDF. #ScaleUp—UNODC initiative on promoting scalable and effective interventions for the treatment of stimulants use disorders: United Nations; 2024.

Darke S, Farrell M. Which medications are suitable for agonist drug maintenance? Addiction. 2016;111:767–74.

Article  PubMed  Google Scholar 

Hall W, Darke S, Farrell M. Do we need clinical trials of high dose stimulant agonist treatment for stimulant use disorders? Addiction. 2024;119:786–7.

Article  PubMed  Google Scholar 

Mattick RP, Darke S. Drug replacement treatments: is amphetamine substitution a horse of a different colour? Drug Alcohol Rev. 1995;14:389–94.

Article  CAS  PubMed  Google Scholar 

Sharafi H, Bakouni H, Mcanulty C, Drouin S, Coronado-Montoya S, Bahremand A, et al. Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: a systematic review and meta-analysis of randomized placebo-controlled trials. Addiction. 2024;119:211–24.

Article  PubMed  Google Scholar 

Ezard N, Clifford B, Siefried K, Ali R, Dunlop A, Mcketin R, et al. Lisdexamfetamine in the treatment of methamphetamine dependence: a randomised, placebo-controlled trial. Addiction. 2025. https://doi.org/10.1111/add.16730.

Article  PubMed  PubMed Central  Google Scholar 

Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med. 2019;380:1128–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tadrous M, Shakeri A, Chu C, Watt J, Mamdani MM, Juurlink DN, et al. Assessment of stimulant use and cardiovascular event risks among older adults. JAMA Netw Open. 2021;4: e2130795–e95.

Article  Google Scholar 

Zhang L, Yao H, Li L, Du Rietz E, Andell P, Garcia-Argibay M, et al. Risk of cardiovascular diseases associated with medications used in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. JAMA Netw Open. 2022;5: e2243597.

Article  PubMed  PubMed Central  Google Scholar 

Bakouni H, Sharafi H, Bahremand A, Drouin S, Ziegler D, Bach P, et al. Bupropion for treatment of amphetamine-type stimulant use disorder: a systematic review and meta-analysis of placebo-controlled randomized clinical trials. Drug Alcohol Depend. 2023;253: 111018.

Article  CAS  PubMed  Google Scholar 

Colfax GN, Santos GM, Das M, Santos DM, Matheson T, Gasper J, et al. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011;68:1168–75.

Article  PubMed  PubMed Central  Google Scholar 

Coffin PO, Santos G-M, Hern J, Vittinghoff E, Walker JE, Matheson T, et al. Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: a placebo-controlled randomized clinical trial. JAMA Psychiatr. 2020;77:246–55.

Article  Google Scholar 

Ray LA, Bujarski S, Courtney KE, Moallem NR, Lunny K, Roche D, et al. The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind, placebo-controlled laboratory study. Neuropsychopharmacology. 2015;40:2347–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bastien G, Mcanulty C, Sharafi H, Mahroug A, Elkrief L, Ziegler D, et al. Is naltrexone effective and safe for treating amphetamine-type stimulant use disorder? A systematic review and meta-analysis. J Addict Med. 2024;19(3):322–30.

Article  PubMed  Google Scholar 

Trivedi MH, Walker R, Ling W, Dela Cruz A, Sharma G, Carmody T, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med. 2021;384:140–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mcketin R, Dean OM, Turner A, Kelly PJ, Quinn B, Lubman DI, et al. N-acetylcysteine (NAC) for methamphetamine dependence: a randomised controlled trial. EClinicalMedicine. 2021;38: 101005.

Article  PubMed  PubMed Central  Google Scholar 

Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11:S133–53.

Article  PubMed  Google Scholar 

Goldstein A. Heroin addiction and the role of methadone in its treatment. Arch Gen Psychiatry. 1972;26:291–7.

Article  CAS  PubMed  Google Scholar 

Jiménez-Ruiz C, Berlin I, Hering T. Varenicline: a novel pharmacotherapy for smoking cessation. Drugs. 2009;69:1319–38.

Article  PubMed  Google Scholar 

Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon Dis. 2008;3:45–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2010;5(5):Cd006103.

Google Scholar 

Yates JR, Broderick MR, Berling KL, Gieske MG, Osborn E, Nelson MR, et al. Effects of adolescent methylphenidate administration on methamphetamine conditioned place preference in an animal model of attention-deficit/hyperactivity disorder: examination of potential sex differences. Drug Alcohol Depend. 2023;252: 110970.

Article  CAS